SEC Form 4 · accession 0001179110-16-017506
Tempest Therapeutics, Inc. · TPST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harald F. Stock
Director
Period of report
Jan 5, 2016
Accepted (ET)
Jan 7, 2016 · 6:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001544227
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 5, 2016 | A | 250,000 | $0.00 | A | 251,228 | D | |
| Common StockF3 | holding | — | — | — | 15,194 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $9.42 | Jan 5, 2016 | A | 250,000 | A | — | Jan 5, 2026 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents the right to receive one share of common stock upon vesting. The RSU vests as to 25% of the shares on January 5, 2017 and as to an additional 6.25% of the shares each successive three-month period thereafter.
- F2Represents 1,228 shares of common stock and 250,000 RSUs.
- F3By SB Vermogensverwaltungs KG, a trust of which the reporting person is a majority shareholder and managing partner.
- F4The option vests as to 25% of the shares on January 5, 2017, and vests as to an additional 6.25% of the shares at the end of each successive three-month period thereafter.